Prognostic Value of Ezrin in Various Cancers: A Systematic Review and Updated Meta-analysis.

Abstract

More and more studies have investigated the effects of Ezrin expression level on the prognostic role in various tumors. However, the results remain controversial rather than conclusive. Here, we performed a systematic review and meta-analysis to evaluate the correlation of Ezrin expression with the prognosis in various tumors. the pooled hazard ratios (HR) with the corresponding 95% confidence intervals (95% CI) were calculated to evaluate the degree of the association. The overall results of fifty-five studies with 6675 patients showed that elevated Ezrin expression was associated with a worse prognosis in patients with cancers, with the pooled HRs of 1.86 (95% CI: 1.51-2.31, P < 0.001) for over survival (OS), 2.55 (95% CI: 2.14-3.05, P < 0.001) for disease-specific survival (DFS) and 2.02 (95% CI: 1.13-3.63, P = 0.018) for disease-specific survival (DSS)/metastasis-free survival (MFS) by the random, fixed and random effect model respectively. Similar results were also observed in the stratified analyses by tumor types, ethnicity background and sample source. This meta-analysis suggests that Ezrin may be a potential prognostic marker in cancer patients. High Ezrin is associated with a poor prognosis in a variety of solid tumors.

• Authors: Jianwei Li, Kuanhai Wei, Hailang Yu, Dan Jin, Gang Wang, Bin Yu
• Journal: Scientific reports (Sci Rep) Vol. 5 Pg. 17903 (Dec 03 2015) ISSN: 2045-2322 [Electronic] England
• PMID: 26632332 (Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic Review)

Chemical References

• Biomarkers, Tumor
• Cytoskeletal Proteins
• ezrin

Topics

• Biomarkers, Tumor (analysis, metabolism)
• Cytoskeletal Proteins (metabolism)
• Disease-Free Survival
• Humans
• Neoplasms (metabolism, mortality)
• Prognosis